Role of prostacyclin in the cardiovascular response to thromboxane A2 - Wikidata - wikimedia - TriplyDB

Role of prostacyclin in the cardiovascular response to thromboxane A2

Role of prostacyclin in the cardiovascular response to thromboxane A2

http://www.wikidata.org/entity/Q28192832

about

sameAs

Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension COX-2 inhibitors: a CLASS act or Just VIGORously promoted Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred Platelet signaling: a complex interplay between inhibitory and activatory networks Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis Dietary polyunsaturated fatty acids and inflammation: the role of phospholipid biosynthesis Drug treatment of pulmonary hypertension in children The Structure of OMCI, a Novel Lipocalin Inhibitor of the Complement System Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks TxA2-mediated myocardial ischemia as a consequence of an acute lung inflammatory reaction in the rabbit Nociceptors in cardiovascular functions: complex interplay as a result of cyclooxygenase inhibition Aspirin resistance: a revival of platelet aggregation tests?Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis Metabonomics reveals drastic changes in anti-inflammatory/pro-resolving polyunsaturated fatty acids-derived lipid mediators in leprosy disease High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function Ribosomal protein L17, RpL17, is an inhibitor of vascular smooth muscle growth and carotid intima formation Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans Epithelial-specific deletion of 11β-HSD2 hinders Apcmin/+ mouse tumorigenesis.Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury Vascular COX-2 modulates blood pressure and thrombosis in mice.Thromboxane A(2) receptor stimulation promotes closure of the rat ductus arteriosus through enhancing neointima formation Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid. "Dioxetane" intermediate versus beta-fragmentation of peroxyl radicals.Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice.The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.Distinct role of Kruppel-like factor 11 in the regulation of prostaglandin E2 biosynthesis.Thromboxane and the thromboxane receptor in cardiovascular disease.Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic st Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.Rationally designed multitarget agents against inflammation and pain.Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline The COXes of Danio: from mechanistic model to experimental therapeutics.

P2860

Q23913301-0AFE4B36-3C8E-449E-84BE-ADF24853BBD0 Q24297600-16CA3FE3-58A7-401D-9C0E-E01C64936D00 Q24338499-94AD97A3-D066-4447-BA81-CE57129070D9 Q24529085-EDA7A18B-89A6-4677-8795-0961A81FA766 Q24796005-5B7A035F-623E-479A-8950-88489CDB3322 Q24804373-CE409916-D4AC-44A3-983F-2CDE9049A3C3 Q26765384-1DB1FAAB-C53D-49A6-BCE1-704B393F3D77 Q26772960-5B69D75B-3E12-4C76-B805-23C81930FA4D Q26865717-4B0A1322-F762-48C9-93C5-E845683F9845 Q26996078-27431121-DB93-4DB9-B29F-2EFA984360DA Q27644514-148CB8C4-50C9-419F-9DCE-7A90EDC312BE Q28167658-1FB793CB-BD6B-475E-AA92-2948BD73D1F7 Q28171125-B7243EDA-BB20-4AD4-964A-92AA90540C01 Q28193254-D3350F51-885F-4DC8-B383-48770BD3B33F Q28196789-CA67E57D-713A-4202-9675-9F0486F36627 Q28200171-3C6F53B2-FCFC-41C8-A388-77C1A40A9EA2 Q28208759-E193C806-21C7-4BCB-BC5B-AAA34D0F7C5E Q28218432-74FA11D3-CFE9-409D-A9BA-F9942CB780BC Q28304230-1F4A9BA1-3089-454A-AF86-1CDE3D7F0EFF Q28534432-40F90903-BA89-4FED-BC94-6FC377450A42 Q28535353-17955A99-BAFF-4E79-90CA-149D3C1B46F7 Q28539230-8DBE3E11-936F-42D8-A4A4-60EADF3F48EF Q28573822-26F9CB6F-9CC6-4FD4-8127-3261742506A4 Q28576245-9E009D83-70F5-4EC2-A62A-5957A7409A08 Q30477135-F3C46607-5E78-4533-8C6C-2F7CEEDBAC8E Q30486725-50E45905-677A-4AB0-B9D2-40F9B73BA53C Q30545576-F043CCB0-1F58-42C3-B28C-B28DBED95C96 Q30557273-BBE28FFA-5AF6-44C5-844E-FB384064C5B0 Q30562262-3A2C3160-3567-46AF-A2DC-B6754CE39BC5 Q31158619-481CF6D4-90F7-4F6E-9781-3F4B67FD9D10 Q33426542-A03452F0-CB38-4756-BEE1-DD3E15AFB965 Q33477092-F1C51EC2-F04A-4D40-AAFB-EA1BE6C19C09 Q33538017-6C00538A-7550-446D-ABD7-F42B69C5A6E8 Q33799761-989AC77D-C39A-443E-A262-2E3326B3F2CB Q33899567-E414393B-33C2-4BBE-B613-0F740A71ADAF Q33920331-6E2D294D-6DDE-42A8-BEAF-4B04179338C7 Q33937192-5C321BCA-8B68-4949-8FE9-0C9890EECF92 Q33960685-8C9016D1-3901-49A4-AD1C-AA07155516FF Q33995716-BF931C17-C4D0-4676-87B0-5A2FDFFF412C Q34033369-DB695F02-1CD5-43EE-A192-37D746D2A52A

P2860

Role of prostacyclin in the cardiovascular response to thromboxane A2

http://www.wikidata.org/entity/Q28192832

description

2002 nî lūn-bûn

@nan

2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Role of prostacyclin in the cardiovascular response to thromboxane A2

@ast

Role of prostacyclin in the cardiovascular response to thromboxane A2

@en

Role of prostacyclin in the cardiovascular response to thromboxane A2

@nl

type

label

Role of prostacyclin in the cardiovascular response to thromboxane A2

@ast

Role of prostacyclin in the cardiovascular response to thromboxane A2

@en

Role of prostacyclin in the cardiovascular response to thromboxane A2

@nl

prefLabel

Role of prostacyclin in the cardiovascular response to thromboxane A2

@ast

Role of prostacyclin in the cardiovascular response to thromboxane A2

@en

Role of prostacyclin in the cardiovascular response to thromboxane A2

@nl

P1433

Q28192832-FC8DD2EE-50D6-4C03-B3F2-2C1D828E3BBD

P1476

Q28192832-09387979-C36D-418A-A785-0B72D5B4CDC1

P2093

Q28192832-2F5371DF-E9C0-47C4-A659-8A42B49E53BA

Q28192832-4CC6C47E-CA7A-4F1A-9799-FADD830E4D1E

Q28192832-6EBBEB27-F09D-4A5E-AD27-EAF3DA7C6387

Q28192832-86197844-1A2E-4445-9F8B-A2362A8FD9D6

Q28192832-B895BB99-6148-49F7-B9D0-94709D7B2683

Q28192832-C52515E8-CF70-4450-8246-8DCA7A96BDAD

Q28192832-D02746F4-0E62-4682-8D03-BF88D7DDF938

P304

Q28192832-D2B299CE-2127-43C0-9C3F-27ADB5702951

P31

Q28192832-35BD18AD-6AB3-484A-A7FA-C0FDB81808DE

P356

Q28192832-50014C4B-0A04-4D03-B8EC-F60DC859B3AD

P407

Q28192832-A1B59E03-D5D1-4596-A357-7A1581E50603

P433

Q28192832-ABBD4FC5-0EB2-414C-BED1-FA6A06C21687

P478

Q28192832-B950B3AD-3A61-4C1F-AA1D-72EFAFDCBF8E

P50

Q28192832-74497C81-8C5C-492F-AC13-FFAF046DB245

P577

Q28192832-D3D24C58-6E08-4095-8E4C-229F4B161E8F

P5875

Q28192832-2A3E3210-7B52-4571-A544-045529A33068

P698

Q28192832-952DEE42-F97F-4DB9-A44E-37A8239E9BE1

P921

Q28192832-D251ECFC-C70E-4089-BB41-134D58AB6026

P356

SCIENCE.1068711

P1433

P1476

Role of prostacyclin in the cardiovascular response to thromboxane A2

@en

P2093

Beverly H Koller

http://www.w3.org/2001/XMLSchema#string

Bianca Rocca

http://www.w3.org/2001/XMLSchema#string

Garret A FitzGerald

http://www.w3.org/2001/XMLSchema#string

John A Lawson

http://www.w3.org/2001/XMLSchema#string

Sandra C Austin

http://www.w3.org/2001/XMLSchema#string

Thomas M Coffman

http://www.w3.org/2001/XMLSchema#string

Yan Cheng

http://www.w3.org/2001/XMLSchema#string

P304

539-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1068711

http://www.w3.org/2001/XMLSchema#string

P407

P433

5567

http://www.w3.org/2001/XMLSchema#string

P478

296

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11402407

http://www.w3.org/2001/XMLSchema#string

P698

11964481

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio